Salute e Benessere

Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial…

"The submission of the protocol marks a major milestone and underscores the focus, commitment and outstanding collaboration across our team and global CRO," said Rahul Agrawal, CMO and Head of R&D of Cereno Scientific. "This protocol has been developed in alignment with the FDA's feedback from our recent Type C meeting, and we now look forward to the agency's review ahead of initiating the trial." "The submission of the protocol marks a major milestone and…
PR Newswire
10/11/2025

GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based…

EVerZom’s investigational drug candidate EViv, developed to treat ACLF, using its proprietary exosome platform, represents a novel approach to regenerative therapies Pending successfulin vivoproof-of-concept results, GENFIT has an exclusive option to take a license to drive EViv into clinical development Under this research collaboration, EVerZom will contribute exosome expertise with associated bioproduction platform, while GENFIT will spearhead preclinical evaluation of...
Nasdaq GlobeNewswire
10/11/2025

GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment…

Preclinical studies demonstrated significant efficacy on systemic inflammation and organ function in ACLF disease modelsSafety data from Phase 1 on healthy volunteers and initial efficacy signals fromex-vivofunctional assays expected by year-end 2025 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025-GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and...
Nasdaq GlobeNewswire
10/11/2025

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows…

The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomideIn a pivotal PPMS study (FENtrepid), fenebrutinib slowed disability progression at least as effectively as OCREVUS, the only approved therapy in PPMSFull data from both studies will be shared at upcoming medical meetings; once the second RMS study (FENhance 1) has read out, which is expected in the first half of 2026,...
Nasdaq GlobeNewswire
10/11/2025

Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting…

Elevated ApoC3 drives triglyceride-rich lipoprotein accumulation, increasing risks of acute pancreatitis and cardiovascular disease, particularly in diabetes. Current therapies often fail to achieve sustained control in severe cases. RN0361's profound, six-month efficacy from a single dose may address this unmet need and marks a significant advance in lipid management. Elevated ApoC3 drives triglyceride-rich lipoprotein accumulation, increasing risks of acute pancreatitis and cardiovascular...
PR Newswire
10/11/2025

ICP DAS-BMP Attends MOU Signing Ceremony to Mark a New Milestone in…

Their combined expertise spans a wide range of sectors, covering medical-grade TPU material manufacturing, smart manufacturing and IIoT applications, precision extrusion machinery and processing technologies, dehumidifying and drying equipment, injection molding and accessory production, catheter manufacturing and OEM molding services, as well as medical device design and regulatory consulting. Their combined expertise spans a wide range of sectors, covering medical-grade TPU material...
PR Newswire
10/11/2025

Zinzino AB (publ.): Zinzino acquires Mexican company Sanki to increase…

Sanki is a direct sales company in the health segment, operating in North America (USA and Mexico) and South America (Colombia and Peru). Its brand portfolio offers a range of innovative and patented products in the field of health and well-being. The business has a total annual turnover of approximately USD 12 million. The collaboration with Zinzino is expected to add growth through the synergies that arise in the joint networks, combined with the integration of Sanki's product portfolio into…
PR Newswire
08/11/2025

Clinically meaningful pivotal study results for olezarsen in sHTG presented as a…

In CORE and CORE2 43% of patients had extremely high levels of triglycerides ≥880 mg/dL, which is often equated to multifactorial chylomicronemia syndrome (MCS) due to the associated increased accumulation of chylomicrons. The effect on triglyceride-lowering and reduction in acute pancreatitis in the MCS subgroup were in line with the overall population. In CORE and CORE2 43% of patients had extremely high levels of triglycerides ≥880 mg/dL, which is often equated to multifactorial...
PR Newswire
08/11/2025

inne Debuts at CIIE with Global Launch of Two New Products

Promoting Standardized Development of Nutritional Products Promoting Standardized Development of Nutritional Products Addressing prevalent issues in the global children's nutrition market concerning ingredient standards, absorption efficiency, and safety regulations, inne® officially released the "Children's Calcium Quality Standard" in collaboration withChina'sleading enterprise JD Health. This standard defines core indicators such as "Calcium Source Safety," "Dosage…
PR Newswire
08/11/2025

Novo Nordisk will not increase its proposal to acquire Metsera, Inc. 

Bagsværd, Denmark, 8 November 2025– Novo Nordisk today confirms that it does not intend to make an increased offer to acquire Metsera. On 30 October 2025, Novo Nordisk announced the submission of an unsolicited proposal to acquire Metsera, Inc. (Metsera) which was declared superior by Metsera’s board of directors. On 4 November 2025, Novo Nordisk confirmed that it had submitted an updated unsolicited proposal to acquire Metsera price of 62.20 USD per share in cash (equal to an...
Nasdaq GlobeNewswire
08/11/2025

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine)…

In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking AUSTEDO or AUSTEDO XRMost (85%) participants taking AUSTEDO or AUSTEDO XR in conjunction with their mental health medications reported that their mental health condition remained stable or improved Teva is committed to truly understanding and empowering individuals living with TD to help improve their...
Nasdaq GlobeNewswire
08/11/2025

Evaxion presents new immune data from phase 2 trial with AI-designed…

New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual MeetingFollowing the recent presentation of unprecedented two-year clinical efficacy data from the phase 2 trial, the new data further adds to EVX-01’s already strong data packageCOPENHAGEN, Denmark, November 7, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data exploring...
Nasdaq GlobeNewswire
07/11/2025

Cellectis Reports Third Quarter 2025 Financial Results and Provides Business…

Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL:Lasme-cel in r/r B-ALL (BALLI-01)ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9)Median OS of 14.8 months in patients who achieved MRD-negative CR/CRi First interim analysis for the BALLI-01 trial expected in Q4 2026 Eti-cel in r/r NHL (NATHALI-01) ORR of...
Nasdaq GlobeNewswire
07/11/2025

Fagron’s share buy-back program: Weekly update

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 7 November 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 3 November 2025 through 7 November 2025, Fagron purchased 45,000 of its owns shares at an average price of €20.4413 per share corresponding to a total amount of €919,856.70. These purchases are part of the share buy-back program of up to 200,000 Fagron shares to fulfill Fagron’s obligations under its long-term incentive scheme,...
Nasdaq GlobeNewswire
07/11/2025

Ipsen - October 2025 - Monthly information relative to the total number of…

Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1) 31 October 202583,814,526Gross total*...
Nasdaq GlobeNewswire
07/11/2025

OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel…

OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel“Cis-Demasking” Cytokine Technology to IncreaseTherapeutic Index of ImmunocytokinesNANTES, France, November 7, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune diseases, presents a poster on its novel OSE-Cytomask® Cis-Demasking 1immunocytokine technology at the Society for Immunotherapy...
Nasdaq GlobeNewswire
07/11/2025

IBA – Regulated information

November 7 th, 2025 Publication made under article 15 of the law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and containing various provisions (Belgian Gazette 12.VI.2007) (hereinafter, the “Law”). Under this provision: « [...] the issuer publishes the total capital, the total...
Nasdaq GlobeNewswire
07/11/2025

Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley

COPENHAGEN, Denmark, November 7, 2025– Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 5,13% of the shares and voting rights in Bavarian Nordic A/S as of October 31, 2025.About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox...
Nasdaq GlobeNewswire
07/11/2025

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights 10/31/2025100,325,45489,406,760For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the...
Nasdaq GlobeNewswire
07/11/2025

Trading by management and close relations of management

Please read the full announcement in PDF Attachment 2025_48_Trading_By_Management
Nasdaq GlobeNewswire
07/11/2025

Preimplantation Genetic Testing Market worth $1,135.0 million by 2030 with 10.5%…

Browse in-depth TOC on "Preimplantation Genetic Testing Market" Browse in-depth TOC on "Preimplantation Genetic Testing Market" 200 - Tables45 - Figures300 - Pages By procedure type,the preimplantation genetic testing market is divided by procedure type into preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD). This growth is primarily driven by the increasing use of PGS to detect chromosomal abnormalities before embryo transfer. End...
PR Newswire
07/11/2025

Virbac : Declaration of the number of shares and voting rights 10/2025

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsOctober, 31 20258 390 660Gross total of voting rights :...
Nasdaq GlobeNewswire
07/11/2025

T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302…

-- Comprehensive TK-6302 data demonstrate preclinical efficacy and safety, supporting clinical readiness, alongside established scalable manufacturing--TK-6302 Clinical Trial Application planned in Q4 2025 for initiation of the Phase 1 ATLAS trial in 2026 SAN FRANCISCO and BERLIN, Nov.07, 2025(GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, today announced multiple...
Nasdaq GlobeNewswire
07/11/2025

2025 Aurora Prize for Awakening Humanity Awarded to Dr. Jamal Eltaeb

Amid Sudan's devastating civil war and the near-total collapse of the country's health system, Dr. Eltaeb has kept Al Nao Hospital in Omdurman operating as one of the last functioning referral hospitals in greater Khartoum—a testament to his resilience and leadership under fire. AmidSudan'sdevastating civil war and the near-total collapse of the country's health system, Dr. Eltaeb has kept Al Nao Hospital in Omdurman operating as one of the last functioning referral hospitals in greater...
PR Newswire
07/11/2025
Altri  Comunicati